Combined therapy of insulin-producing cells and haematopoietic stem cells offers better diabetic control than only haematopoietic stem cells' infusion for patients with insulin-dependent diabetes

BMJ Case Rep. 2014 Sep 8:2014:bcr2013201238. doi: 10.1136/bcr-2013-201238.

Abstract

Insulin-dependent diabetes mellitus (IDDM) is a chronic condition characterised by impaired blood sugar metabolism and autoimmunity. We report two children: a 5-year-old girl on exogenous insulin therapy of 30 IU/day and a 9-year-old boy on short-acting insulin 30 IU/day, long-acting insulin 70 IU/day, with IDDM since 4 and 7 years, respectively. We infused in vitro-generated donor bone marrow (BM)-derived haematopoietic stem cells (HSC) in patient 1 and insulin-secreting cells trans-differentiated from autologous adipose tissue-derived mesenchymal stem cells along with BM-HSC in patient 2 under non-myeloablative conditioning. Patient 1 improved during the initial 6 months, but then again lost metabolic control with increased blood sugar levels and insulin requirement of 32 IU/day; we lost her to follow-up after 18 months. Patient 2, over follow-up of 24.87 months, has stable blood sugar levels with glycosylated haemoglobin of 6.4% and present insulin requirement of 15 IU/day.

Publication types

  • Case Reports

MeSH terms

  • Adipose Tissue
  • Blood Glucose / metabolism
  • Cell Differentiation
  • Child
  • Child, Preschool
  • Diabetes Mellitus, Type 1 / blood
  • Diabetes Mellitus, Type 1 / surgery*
  • Female
  • Glycated Hemoglobin / metabolism
  • Hematopoietic Stem Cell Transplantation*
  • Hematopoietic Stem Cells*
  • Humans
  • Insulin* / therapeutic use
  • Insulin-Secreting Cells / transplantation*
  • Male
  • Mesenchymal Stem Cell Transplantation*
  • Mesenchymal Stem Cells*

Substances

  • Blood Glucose
  • Glycated Hemoglobin A
  • Insulin